Performance characteristics of plasma amyloid-β 40 and 42 assays

Journal of Alzheimer's Disease

Volumn 16, Issue 2, 2009, Pages 277-285

  Okereke, Olivia I ^a,g   Xia, Weiming ^b   Irizarry, Michael C ^b,h   Sun, Xiaoyan ^c   Qiu, Wei Q ^c   Fagan, Anne M ^d   Mehta, Pankaj D ^e   Hyman, Bradley T ^b   Selkoe, Dennis J ^b   Grodstein, Francine ^a,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g CHANNING LABORATORY   (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Assay reliability; Biomarker; Quality control

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; EDETIC ACID; HEPARIN;

ARTICLE; BLOOD; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN STABILITY; RELIABILITY;

EID: 60349123096     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0948     Document Type: Article

References (20)

1. DeKosky ST, Marek K (2003) Looking backward to move forward: early detection of neurodegenerative disorders. Science 302, 830-834.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
3. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2, 864-870.
4. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105.
5. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60, 958-964.
6. Irizarry MC (2004) Biomarkers of Alzheimer disease in plasm. NeuroRx 1, 226-234.
7. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61, 1185-1190.
8. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660.
9. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362. Erratum in: Arch Neurol 64, 1246.
10. Sundelöf J, Giedraitis V, Irizarry MC, Sundström J, Ingelsson E, Rönnemaa E, Arnlöv J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L (2008) Plasma Aβ and the risk of Alzheimer's disease and dementia in elderly men: a prospective population-based cohort study. Arch Neurol 65, 256-623.
11. Blanck HM, Bowman BA, Cooper GR, Myers GL, Miller DT (2003) Laboratory issues: use of nutritional biomarkers. J Nutr 133, 888S-894S.
12. Tworoger SS, Hankinson SE (2006) Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Cancer Causes Control 17, 889-899.
13. Rosner BA (1995) Fundamentals of Biostatistics, Fourth ed., Duxbury Press, Belmont, CA, p. 519.
14. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13, 1029-1031.
15. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP (2001) Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304, 102-106.
16. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF (1994) Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67, 1216-1228.
17. Vanderstichele H, Demeyer L, Vandecasteele L, Decraemer H, Van Remoortere S, Catry C, De Meyer G, Kostanjevecki V, Vanmechelen E (2007) P-064 Measurement of β-amyloid isoforms in human plasma using the INNO-BIA plasma Aβ forms: (Pre)-clinical validation. Alzheimers Dement 3, S119.
18. Myers GL, Kimberly MM, Waymack PP, Smith SJ, Cooper GR, Sampson EJ (2000) A reference method laboratory network for cholesterol: a model for standardization and improvement of clinical laboratory measurements. Clin Chem 46, 1762-1772.
19. Roberts WL (2004) CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation-performance and standardization: a background paper. Circulation 110, e572-576.
20. Bateman RJ, Wen G, Morris JC, Holtzman DM (2007) Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68, 666-669.